800 related articles for article (PubMed ID: 38311377)
1. Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.
Song B; Yang P; Zhang S
Cancer Commun (Lond); 2024 Mar; 44(3):297-360. PubMed ID: 38311377
[TBL] [Abstract][Full Text] [Related]
2. A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications.
Wang M; Attardi LD
Annu Rev Pathol; 2022 Jan; 17():205-226. PubMed ID: 34699262
[No Abstract] [Full Text] [Related]
3. Recent advances in p53 research and cancer treatment.
Suzuki K; Matsubara H
J Biomed Biotechnol; 2011; 2011():978312. PubMed ID: 21765642
[TBL] [Abstract][Full Text] [Related]
4. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies.
Harris CC
J Natl Cancer Inst; 1996 Oct; 88(20):1442-55. PubMed ID: 8841019
[TBL] [Abstract][Full Text] [Related]
5. Targeting p53 pathways: mechanisms, structures, and advances in therapy.
Wang H; Guo M; Wei H; Chen Y
Signal Transduct Target Ther; 2023 Mar; 8(1):92. PubMed ID: 36859359
[TBL] [Abstract][Full Text] [Related]
6. TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress.
Zhu KL; Su F; Yang JR; Xiao RW; Wu RY; Cao MY; Ling XL; Zhang T
Mol Biol Rep; 2024 Jan; 51(1):205. PubMed ID: 38270700
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in p53.
D'Orazi G
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33546313
[TBL] [Abstract][Full Text] [Related]
8. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
9. Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe.
Asl ER; Rostamzadeh D; Duijf PHG; Mafi S; Mansoori B; Barati S; Cho WC; Mansoori B
Life Sci; 2023 Feb; 315():121361. PubMed ID: 36608871
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.
Chen X; Zhang T; Su W; Dou Z; Zhao D; Jin X; Lei H; Wang J; Xie X; Cheng B; Li Q; Zhang H; Di C
Cell Death Dis; 2022 Nov; 13(11):974. PubMed ID: 36400749
[TBL] [Abstract][Full Text] [Related]
11. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.
Zhang S; Carlsen L; Hernandez Borrero L; Seyhan AA; Tian X; El-Deiry WS
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454137
[No Abstract] [Full Text] [Related]
12. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage.
Yoshida K; Miki Y
Cancer Sci; 2010 Apr; 101(4):831-5. PubMed ID: 20132225
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppressive functions of p53.
Zilfou JT; Lowe SW
Cold Spring Harb Perspect Biol; 2009 Nov; 1(5):a001883. PubMed ID: 20066118
[TBL] [Abstract][Full Text] [Related]
14. Understanding the complexity of p53 in a new era of tumor suppression.
Liu Y; Su Z; Tavana O; Gu W
Cancer Cell; 2024 Jun; 42(6):946-967. PubMed ID: 38729160
[TBL] [Abstract][Full Text] [Related]
15. Understanding p53 tumour suppressor network.
Panatta E; Zampieri C; Melino G; Amelio I
Biol Direct; 2021 Aug; 16(1):14. PubMed ID: 34362419
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-Mutant P53 Crosstalk in Chemoresistance: A Hint to Monitor Therapy Outcome.
Speciale A; Monti P; Fronza G; Izzotti A; Menichini P
Microrna; 2020; 9(5):322-335. PubMed ID: 33297928
[TBL] [Abstract][Full Text] [Related]
17. Targeting the DNA Damage Response in OSCC with TP53 Mutations.
Lindemann A; Takahashi H; Patel AA; Osman AA; Myers JN
J Dent Res; 2018 Jun; 97(6):635-644. PubMed ID: 29489434
[TBL] [Abstract][Full Text] [Related]
18. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
20. p53: the attractive tumor suppressor in the cancer research field.
Ozaki T; Nakagawara A
J Biomed Biotechnol; 2011; 2011():603925. PubMed ID: 21188172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
